I've got a full-time job http://xnxxxnxxcom.in.net/ japan xxx Afatinib's safety and effectiveness were evaluated in clinical studies involving 345 people with spreading NSCLC whose tumors had EGFR mutations. Among those who received afatinib, progression-free survival was 4.2 months longer than for those who received chemotherapy, the FDA said. There was no statistically significant difference in overall survival, the agency added.